Evidence map›Paper›PMID 39465557›Full record

ArticleJournal of diabetes science and technology2026

Twelve-Month Real-World Use of an Advanced Hybrid Closed-Loop System Versus Previous Therapy in a Dutch Center For Specialized Type 1 Diabetes Care.

Pim Dekker, Tim van den Heuvel, Arcelia Arrieta, Javier Castañeda, Dick Mul, Henk Veeze, Ohad Cohen, Henk-Jan Aanstoot

Abstract read
In one paragraph

Article in Journal of diabetes science and technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Real-World Glucometric Outcomes of the MiniMed 780G Advanced Hybrid Closed-Loop System in Users with Type 1 Diabetes in Spain.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Pim DekkerCentre for Pediatric and Adult Diabetes Care and Research, Diabeter, Rotterdam, The Netherlands.ORCID 0000-0002-1405-8460
Tim van den HeuvelMedtronic Bakken Research Center, Maastricht, The Netherlands.
Arcelia ArrietaMedtronic Bakken Research Center, Maastricht, The Netherlands.
Javier CastañedaMedtronic Bakken Research Center, Maastricht, The Netherlands.
Dick MulCentre for Pediatric and Adult Diabetes Care and Research, Diabeter, Rotterdam, The Netherlands.
Henk VeezeCentre for Pediatric and Adult Diabetes Care and Research, Diabeter, Rotterdam, The Netherlands.
Ohad CohenMedtronic International Trading Sàrl, Tolochenaz, Switzerland.
Henk-Jan AanstootCentre for Pediatric and Adult Diabetes Care and Research, Diabeter, Rotterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundComplexity of glucose regulation in persons with type 1 diabetes (PWDs) necessitates increased automation of insulin delivery (AID). This study aimed to analyze real-world data over 12 months from PWDs who started using the MiniMed 780G (MM780G) advanced hybrid closed-loop (aHCL) AID system at the Diabeter clinic, focusing on glucometrics and clinical outcomes.

methodsPersons with type 1 diabetes switching to the MM780G system were included. Clinical data (e.g. HbA1c, previous modality) was collected from Diabeter's electronic health records and glucometrics (time in range [TIR], time in tight range [TITR], time above range [TAR], time below range [TBR], glucose management indicator [GMI]) from CareLink Personal for a 12-month post-initiation period of the MM780G system. Outcomes were age-stratified, and the MM780G system was compared with previous use of older systems (MM640G and MM670G). Longitudinal changes in glucometrics were also evaluated.

resultsA total of 481 PWDs were included, with 219 having prior pump/sensor system data and 334 having monthly longitudinal data. After MM780G initiation, HbA1c decreased from 7.6 to 7.1% (

conclusionsUse of MM780G system results in significant and sustained glycemic improvements, consistent across age groups and irrespective of previous treatment modalities.

Indexed as

Diabetes Mellitus, Type 1Hypoglycemic AgentsInsulinInsulin Infusion SystemsAdolescentAdultAgedBlood GlucoseBlood Glucose Self-MonitoringFemaleGlycated HemoglobinGlycemic ControlHumansMaleMiddle AgedNetherlandsBlood GlucoseGlycated HemoglobinHypoglycemic AgentsInsulin780Gadvanced hybrid closed-loopautomated insulin deliverytype 1 diabetes

Identifiers

PMID39465557
PMCPMC11571609

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.